肿瘤药学2026，Vol.16Issue(3)：300-309,10.DOI:10.3969/j.issn.2095-1264.2026.03.06
维泊妥珠单抗在弥漫大B细胞淋巴瘤治疗中的研究进展
Research progress of polatuzumab vedotin in the treatment of diffuse large B-cell lymphoma
摘要
Abstract
Despite continuous advancements in the treatment of diffuse large B-cell lymphoma(DLBCL),including R-CHOP chemotherapy,CAR-T cell therapy,and hematopoietic stem cell transplantation,a substantial proportion of patients still experience relapse or exhibit refractory disease to first-line regimens,underscoring the urgent need for novel therapeu-tic strategies.Polatuzumab vedotin,an antibody-drug conjugate targeting CD79b,has garnered significant attention follow-ing its positive outcomes in the phase Ⅲ POLARIX trial,where it was combined with rituximab,cyclophosphamide,doxoru-bicin,and prednisone(Pola-R-CHP).This review elucidates the structure,mechanism of action,and current clinical appli-cations of polatuzumab vedotin in DLBCL.Furthermore,it addresses the existing limitations of this agent and proposes po-tential countermeasures,aiming to provide a theoretical foundation for optimizing its role in the DLBCL treatment land-scape.关键词
弥漫大B细胞淋巴瘤/维泊妥珠单抗/抗体药物偶联物Key words
Diffuse large B-cell lymphoma/Polatuzumab vedotin/Antibody-drug conjugates分类
医药卫生引用本文复制引用
刘姗,郭智..维泊妥珠单抗在弥漫大B细胞淋巴瘤治疗中的研究进展[J].肿瘤药学,2026,16(3):300-309,10.基金项目
深圳市医学研究专项资金项目(B2402027)、国家卫生健康委员会核技术医学转化重点实验室开放课题(2023HYX033) （B2402027）
南山区区级医学重点学科建设资助项目. （）
